Dwyer R, Ortqvist A, Aufwerber E, Henriques Normark B, Marrie T J, Mufson M A, Torres A, Woodhead M A, Alenius M, Kalin M
Department of Medicine, Infectious Disease Unit, Karolinska University Hospital, 14186 Stockholm, Sweden.
Eur J Clin Microbiol Infect Dis. 2006 Aug;25(8):518-21. doi: 10.1007/s10096-006-0183-2.
In the study presented here, data collected prospectively from 340 adult patients hospitalised in five countries with bacteremic pneumococcal CAP and treated with a ss-lactam +/- a macrolide were analysed retrospectively to evaluate the efficacy of this antimicrobial combination. Univariate and multivariate analyses revealed no significant effect on case fatality rate when a macrolide/ss-lactam regimen was used as initial therapy. Results were not affected by severity of illness, or by excluding patients who died within 2 days of admission. Identified predictors of death in a multivariate regression model were age >65 years (OR=2.6), two or more lung lobes affected (OR=2.2), and severity of disease as estimated using the acute physiology score (APS)>8.
在本研究中,回顾性分析了从五个国家住院治疗的340例成年菌血症性肺炎球菌社区获得性肺炎(CAP)患者前瞻性收集的数据,这些患者接受了β-内酰胺类药物加/不加大环内酯类药物治疗,以评估这种抗菌药物联合治疗的疗效。单因素和多因素分析显示,当使用大环内酯类/β-内酰胺类药物方案作为初始治疗时,对病死率没有显著影响。结果不受疾病严重程度的影响,也不受排除入院后2天内死亡患者的影响。多因素回归模型中确定的死亡预测因素为年龄>65岁(比值比[OR]=2.6)、两个或更多肺叶受累(OR=2.2)以及使用急性生理学评分(APS)评估的疾病严重程度>8。